2 minute read
Our Corporate Patron
Next Article
One Nucleus is delighted that AstraZeneca will continue its long-held relationship as Corporate Patron. Over the decade of support to date, AstraZeneca has provided a number of its leadership as Board members, delivered strategic guidance as one of the region’s key stakeholders and presented thought-leaders for our key annual events. The breadth of this engagement means we have formed a strong and productive relationship with AstraZeneca, based on shared ambitions for the Cambridge and wider UK life sciences community.
Driven by innovative science and an entrepreneurial culture, in 2019, AstraZeneca announced a simplified organisation designed to position itself ready for its next stage of strategic development. The changes further integrated research and development to enhance innovation and deliver sustainable growth.
Highlighting AstraZeneca’s commitment to the partnership with One Nucleus, it is with pleasure that we recently welcomed Penny James, Chief Operating Officer BioPharmaceutical R&D, to the One Nucleus Board.
The shared ambitions for the region’s life science cluster to be the world-leading bioinnovation hub is key to both of our organisations. One Nucleus strives to enable knowledge sharing on the latest innovations in the scientific, business and investment aspects of the sector. AstraZeneca’s willingness to dedicate strategic resource to us, such as event speakers and updates, significantly enhances our delivery. Their engagement provides insight to the nascent companies, their founding entrepreneurs and investors, on how exceptional scientific innovation can be translated into patient benefit globally. This fits well with the collective aspirations of our cluster’s ecosystem; to create life changing technologies and products that have a global impact on lives.
AstraZeneca’s role as a global leader and regional champion has never been more evident as in their response to the COVID-19 pandemic. Its partnership with the University of Cambridge and GSK was key to the creation of the Cambridge COVID-19 Testing Centre on the Cambridge Biomedical Campus to support the government’s national screening programme.
This, in addition to their focus in finding new preventative and treatment approaches to combat the pandemic, exemplifies why the UK has such a strong reputation in life science innovation. Their dedication to supporting the UK’s efforts to fight COVID-19 gives even extra pleasure to count AstraZeneca as the One Nucleus Corporate Patron.
AstraZeneca has been headquartered in Cambridge since 2016, and now has more than 3,000 employees in the area. AstraZeneca continues the build of its Global R&D facility on the Cambridge Biomedical Campus with the involvement of Ms James on the Programme Board.
AstraZeneca is as deeply committed to our life science community as we are at One Nucleus. As well as world class science, AstraZeneca has collaboration at its core, and we look forward to working collaboratively with our them to the benefit of our members and to the benefit of our sector, in Cambridge and beyond.
Tony Jones, CEO
Laboratory of Molecular Biology
Energy & Data Centre and planned R&D Enabling Building
Anne McLaren Laboratory of Regenerative Medicine R&D centre under construction Milner Research Labs Functional Genomics Centre
Cambridge Institute
School of Clinical Medicine
Opened 9th July 2019
